Advertisement
"This partnership in the U.S. will enable us to increase the oraltreatment options for people with type 2 diabetes to help them gain goodglycemic control," said Martin Soeters, president of Novo Nordisk Inc. "Itwill also allow Novo Nordisk to concentrate on bringing our complete portfolioof three insulin analogs to health care providers, which provides the mostviable opportunity to both help improve patient outcomes and realize ourbusiness aspirations, in the name of Changing Diabetes(R)."
Advertisement
Patrick Fourteau, president and CEO of Sciele Pharma, Inc., added, "We arepleased to initiate this partnership with Novo Nordisk, a company that iswidely recognized as a global leader in diabetes care. Prandin(R) fits wellwithin our Diabetes product portfolio and will be an excellent complement toFortamet(R). Promoted by our Primary Care sales force, Prandin(R) willstrengthen our presence in the diabetes treatment market."
About Prandin(R)
Prandin(R) is an oral blood glucose-lowering drug of the meglitinide classused in the management of type 2 diabetes mellitus. PrandiMet(R) is acombination tablet of repaglinide and metformin, which has yet to be approvedby the FDA.
Prandin(R) is indicated as an adjunct to diet and exercise for patientswith type 2 diabetes whose hyperglycemia cannot be controlled satisfactorilyby diet and exercise alone. Prandin(R) is also indicated for combinationtherapy use (with metformin or thiazolidinediones) for patients whosehyperglycemia cannot be controlled by diet and exercise plus monotherapy withany of the following agents: metformin, sulfonylureas, repaglinide, orthiazolidinediones.
Prandin(R) is contraindicated in patients with diabetic ketoacidosis (withor without coma, type 1 diabetes, or known hypersensitivity to the drug or itsinactive ingredients. Prandin(R) is not indicated for use in combination withNPH insulin. All oral blood glucose-lowering drugs, including Prandin(R), arecapable of producing hypoglycemia. Full prescribing information is availableat novonordisk-us.com.
Financial terms of the agreement are not being disclosed.
About Novo Nordisk Inc.
Novo Nordisk is a healthcare company with an 84-year history of innovationand achievement in diabetes care. The company has the broadest diabetesproduct portfolio in the industry, including the most advanced products withinthe area of insulin delivery systems. In addition to diabetes care, NovoNordisk has a leading position within areas such as hemostasis management,growth hormone therapy, and hormone therapy for women. Novo Nordisk's businessis driven by the Triple Bottom Line: a commitment to economic success,environmental soundness, and social responsibility to employees and customers.With headquarters in Denmark, Novo Nordisk employs more than 25,800 employeesin 79 countries, and markets its products in 179 countries. Novo Nordisk's Bshares are listed on the stock exchanges in Copenhagen and London. Its ADRsare listed on the New York Stock Exchange under the symbol 'NVO'. For globalinformation, visit novonordisk.com; for United States information, visitnovonordisk-us.com.
About Sciele Pharma, Inc.
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales,marketing and de
